Show simple item record

dc.contributor.authorNeuzil, Kathleen M
dc.contributor.authorBasnyat, Buddha
dc.contributor.authorClemens, John D
dc.contributor.authorGordon, Melita A
dc.contributor.authorPatel, Priyanka D
dc.contributor.authorPollard, Andrew J
dc.contributor.authorShakya, Mila
dc.contributor.authorQadri, Firdausi
dc.date.accessioned2020-08-13T13:53:27Z
dc.date.available2020-08-13T13:53:27Z
dc.date.issued2020-07-29
dc.identifier.urihttp://hdl.handle.net/10713/13537
dc.description.abstractClinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries. Early data confirm safety, tolerability, and immunogenicity of typhoid conjugate vaccine, and early efficacy results are promising. These data support World Health Organization recommendations and planned country introductions. Forthcoming trial data will continue to inform programmatic use of typhoid conjugate vaccine. © The Author(s) 2020.en_US
dc.description.urihttps://doi.org/10.1093/cid/ciaa370en_US
dc.language.isoen_USen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofClinical Infectious Diseasesen_US
dc.rights© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.en_US
dc.subjectTyVACen_US
dc.subjectclinical trialsen_US
dc.subjectconjugate vaccineen_US
dc.subjecttyphoiden_US
dc.titleEarly Insights From Clinical Trials of Typhoid Conjugate Vaccineen_US
dc.typeArticleen_US
dc.identifier.doi10.1093/cid/ciaa370
dc.identifier.pmid32725230
dc.source.volume71
dc.source.issueSupplement_2
dc.source.beginpageS155
dc.source.endpageS159
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record